prikaz prve stranice dokumenta Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases
  Download
PDF 3.13 MB
Scientific paper - Original scientific paper
Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases
HemaSphere, 6 (2022), 12; e807. https://doi.org/10.1097/HS9.0000000000000807
Galušić, Davor; Bašić-Kinda, Sandra; Pijuk, Anđela; Milunović, Vibor; Dreta, Barbara; Franjić, Neven; Coha, Božena; Sinčić-Petričević, Jasminka; Gaćina, Petar; Pejsa, Vlatko; Lucijanić, Marko; Aurer, Igor

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Galušić, D., Bašić Kinda, S., Pijuk, A., Milunović, V., Dreta, B., Franjić, N. ... Aurer, I. (2022). Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases. HemaSphere, 6. (12). doi: 10.1097/HS9.0000000000000807

Galušić, Davor, et al. "Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases." HemaSphere, vol. 6, no. 12, 2022. https://doi.org/10.1097/HS9.0000000000000807

Galušić, Davor, Sandra Bašić Kinda, Anđela Pijuk, Vibor Milunović, Barbara Dreta, Neven Franjić, Božena Coha, et al. "Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases." HemaSphere 6, no. 12 (2022). https://doi.org/10.1097/HS9.0000000000000807

Galušić, D., et al. (2022) 'Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases', HemaSphere, 6(12). doi: 10.1097/HS9.0000000000000807

Galušić D, Bašić Kinda S, Pijuk A, Milunović V, Dreta B, Franjić N, and sur.. Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases. HemaSphere [Internet]. 2022 December [cited 2024 November 27];6(12). doi: 10.1097/HS9.0000000000000807

D. Galušić, et al., "Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases", HemaSphere, vol. 6, no. 12, December 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:450646. [Accessed: 27 November 2024]

Metadata
Title (english)Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases
AuthorDavor Galušić
AuthorSandra Bašić-Kinda
AuthorAnđela Pijuk
AuthorVibor Milunović
AuthorBarbara Dreta
AuthorNeven Franjić
AuthorBožena Coha
AuthorJasminka Sinčić-Petričević
AuthorPetar Gaćina
AuthorVlatko Pejsa
AuthorMarko Lucijanić
AuthorIgor Aurer
Author's institution(Clinical Hospital Center Rijeka)
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Infectology
Abstract (croatian)
Obinutuzumab (G) has become part of front-line treatment of follicular lymphoma (FL) based on results of a large randomized study. Data on patients treated outside of clinical trials are lacking. We have retrospectively investigated efficacy and safety of G-based immunochemotherapy regimens in 114 patients treated in a real-life setting during a period of 2 years, largely coinciding with the COVID-19 pandemic. The response rate was 93.8%; 18-months overall (OS) and progression-free survival (PFS) were 88% and 84%, respectively. Patients treated with G-cyclophosphamide, vincristine and glucocorticoid + doxorubicine (CHOP) had statistically significantly superior OS and PFS compared to patients treated with G-bendamustine (G-B) (P = 0.002 and P = 0.006, respectively) due to an increase in lethal infections, most notably COVID-19, in the latter group. A total of 12 patients died during follow-up; 9 of 61 treated with G-B, 1 of 49 treated with G-CHOP and 2 of 4 treated with G-cyclophosphamide, vincristine and glucocorticoid (CVP). SARS-CoV-2 infection was diagnosed in 20 (17.5%) patients. All of the 7 treated with G-CHOP recovered, while 4 of 12 treated with G-B died. Immunoglobulin levels and severity of neutropenia were similar between the groups. In multivariate analysis, G-B in comparison to G-CHOP was an independent prognostic factor (P = 0.044, hazard ratio = 9.81) after adjustment for age, sex and Follicular Lymphoma International Prognostic Index (FLIPI). Based on our experience G has excellent antilymphoma activity in patients receiving front-line treatment for FL in real-life setting, but during the COVID-19 pandemic, it should be preferentially combined with CHOP, at least in patients younger than 65.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleHemaSphere
Numberingvol. 6, no. 12, e807
e-ISSN2572-9241
DOIhttps://doi.org/10.1097/HS9.0000000000000807
URN:NBNurn:nbn:hr:184:450646
Publication2022-12
Document URLhttps://journals.lww.com/10.1097/HS9.0000000000000807
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) icon
Created on2023-02-01 08:14:04